Start-Ups
Expert scientific, regulatory, and clinical support for early-stage biotechs to de-risk development and reach milestones faster.
hvivo.comCrawled Nov 17, 2026
Expert scientific, regulatory, and clinical support for early-stage biotechs to de-risk development and reach milestones faster.
Clinical pharmacology services: first-in-human (FIH), SAD/MAD, BA/BE, drug-drug, food-effect and QT/QTc studies. Phase I units in UK and Germany.
The page outlines five key questions to assess whether custom assay design is needed for a novel therapeutic program.
HTA-licensed, Home Office approved sample storage and biobanking in Greenwich, London. Cryostorage from ambient to -196°C for clinical samples and IMPs.
Deep therapeutic expertise across infectious disease, respiratory, renal, hepatic, cardiometabolic, dermatology, and ophthalmology trial design.
hVIVO hosts conferences, webinars, and workshops across therapeutic areas, with on-demand sessions available.
hVIVO offers a library of scientific resources, including articles and papers, for drug development and clinical research.
hVIVO provides articles, webinars, workshops, and events supporting all stages of clinical development.
hVIVO hosts expert-led webinars on clinical development, infectious disease, and human challenge models.
hVIVO outlines its strategic evolution into a full-service clinical development partner at Capital Markets Day 2026.
Media coverage and press mentions feature hVIVO’s work in human challenge and clinical research.
hVIVO provides updates on clinical trial milestones, partnerships, and scientific publications.
hVIVO shares news, media coverage, and insights on human challenge trials and early-phase clinical development.
hVIVO offers press kit materials, including logos, brand guidelines, and leadership photographs.
hVIVO lists job openings in clinical operations, laboratory sciences, medical writing, and drug development consulting.
Adam French, with over 20 years in the pharmaceutical and CRO industry, drives operational excellence and strategic transformation at hVIVO.
André Wolterbeek leads non-clinical development with over 25 years of CRO experience, specialising in preclinical studies and regulatory compliance.
Caroline Shaw CBE is a senior healthcare executive with extensive experience across healthcare delivery, clinical leadership, operational transformation and life sciences.
Chris Forsdyke, an expert in drug development, leads high-performance teams and fosters client partnerships to deliver impactful therapies.
Dr Bevan has 12 years of clinical experience, specializing in respiratory research, human challenge trials, and asthma/COPD studies.
Erik Gout, 40+ years in pharmaceutical CMC. Leads hVIVO's CMC workstream and supports early-phase drug development programmes.
Independent scientific, clinical and regulatory due diligence for investors. Assess risk, identify value and support portfolio decisions.
hVIVO is a leading CRO specialising in human challenge models, clinical trials, and laboratory services. AIM-listed and London-headquartered.
hVIVO plc follows the QCA Code 2023 and its 10 principles for corporate governance.
Upcoming and past investor events, capital markets presentations, and roadshow schedules for hVIVO Services plc.
A purpose-built Clinical Research Organisation deliberately created to offer expert-led drug development services at all stages of the development cycle.
Partner with hVIVO for clinical research, human challenge studies, and drug development. Academic, biotech, and pharma collaboration opportunities.
hVIVO provides contact details for clinical trial, laboratory, and consulting inquiries.
hVIVO offers paid clinical trials in London, including human challenge and Phase I studies with medical support.
World-leading human challenge company with 30+ years of experience. Integrated clinical, laboratory and consulting services across UK and Europe.
hVIVO’s privacy policy for Business Partners and Prospective Clients describes data processing and protection measures.
hVIVO explains how it processes personal data during recruitment and outlines data protection commitments.
hVIVO details how it collects, uses, and protects personal data in compliance with data protection laws.
The Data Processing Addendum for hVIVO B.V. consultancy services, setting out how hVIVO processes client personal data as a Processor under GDPR.
Links to key legal agreements for hVIVO
hVIVO Services Limited commits to ethical business practices, actively combating modern slavery in its organisation and supply chain.
hVIVO’s terms of use outline rights, account policies, intellectual property, and privacy policy links.
hVIVO PLC acquires CRS Berlin to strengthen its clinical research capabilities in dermatology and women’s health. The move extends the company’s service offerings into specialized therapeutic areas. The deal follows hVIVO’s strategic focus on diversifying its clinical trial expertise.
hVIVO acquires CRS Clinical Research Services Berlin GmbH, a Phase I/II clinical research unit specializing in dermatology and women’s health trials. The move expands hVIVO’s capabilities in these therapeutic areas, leveraging CRS Berlin’s expertise in early-stage dermatology and women’s health studies. The acquisition strengthens hVIVO’s footprint in Germany’s clinical research sector.
hVIVO’s order book more than doubled to **£65 million** in the first half of 2026, up from **£30 million** at the start of the year. The company reports **£16.3 million** in H1 revenue and projects **high-single-digit full-year growth**, driven by strong backlog demand. Management highlights a **second-half-weighted** performance trajectory for 2026.
hVIVO provides Decoy Therapeutics with consultancy services for respiratory antiviral development. The agreement covers translational modeling, regulatory strategy, and clinical submission preparation. Decoy Therapeutics focuses on antiviral therapies targeting respiratory diseases.
hVIVO’s German subsidiary CRS secures £5 million in early-phase clinical trial service contracts after being acquired by hVIVO. The contracts support the subsidiary’s expansion in clinical research services for pharmaceutical development.
Hvivo wins a **£2.7 million contract**, its largest to date, as it expands into standalone services. The company recently relocated to a new Canary Wharf facility, tripling its laboratory capacity to support growth. This deal reflects its push into broader commercial offerings beyond core operations.

hVIVO runs early phase human challenge trials for drug developers as a full-service clinical research organisation.